THE PREVALENCE OF ANTIBODIES AGAINST JOHN CUNNINGHAM VIRUS IN PATIENTS WITH MULTIPLE SCLEROSIS – AS A STRATIFICATION OF THE PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY RISK DEGREE AT THIS DISEASE
Introduction. Progressive multifocal leukoencephalopathy (PML) is a rare and severe demyelinating disease of the white matter of the central nervous system (CNS) and caused by the John Cunningham virus (JCV). JCV infection has become important for neurologists after reporting two cases of PML in patients with multiple sclerosis (MS) treated with natalizumab.
Aim: To study the prevalence of antibodies against John Cunningham virus (JCV) in patients with multiple sclerosis and identify the relationship between clinical, demographic characteristics and seropositivity and seronegativity for anti-JCV.
Materials and methods. We conducted a retrospective assessment of a database of MS patients registered at the Multiple Sclerosis Center of Almaty, who are candidates for natalizumab, from April 2018 to June 2019. The diagnosis was diagnosed in accordance with 2017 MacDonald's revised criteria. Several factors were studied, such as age, gender, nationality, duration of illness, average score on the advanced EDSS disability rating scale, to determine cognitive function on the MOCA scale during testing for anti-JCV antibodies and previous immunotherapy. The relationship between the seropositivity of the anti-JCV antibody and the demographic characteristics and disease characteristics was evaluated.
Research results: Of the 71 examined patients with MS for the presence of antibodies against the JC virus, 76.1% were women (54) and 23.9% were men (17). The average age was 41.2 ± 11.4 years, and the duration of the disease was 11.9 ± 8.7 years. Most patients 77.5% (55) had relapsing - remitting MS, and the average EDSS score in the study group was 3.75 ± 1.45 points. The overall prevalence of seropositivity for anti-JC virus antibody was 85.9% (61), of which 73.8% were women.
Conclusions: Thus, the study confirmed the high prevalence of anti-JCV antibodies in patients with MS by 85.9%. The results of studies conducted to date confirm the prognostic value of measuring anti-JCV antibodies in assessing the risk of PML, however, changes in JCV status must be considered.
Number of Views: 447
Category of articles:
Original articles
Bibliography link
Sharapkhanova A.M., Kamenova S.U., Kuzhybaeva K.K., Kondybayeva A.M. The prevalence of antibodies against John Cunningham virus in patients with multiple sclerosis – as a stratification of the progressive multifocal leukoencephalopathy risk degree at this disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2020, (Vol.22) 1, pp. 64-71. doi:10.34689/SH.2020.22.1.007Related publications:
VALIDATION OF THE KAZAKH VERSION OF THE DEPRESSION ANXIETY STRESS SCALE (DASS-21) IN MEDICAL FACULTY STAFF SAMPLE: THE PILOT STUDY
PREDICTIVE VALUE OF PSYCHOMETRIC TESTING IN CONTEXT OF CREATING ADAPTIVE ENVIRONMENT FOR HIGHER MEDICAL EDUCATION
ASSESSMENT OF STUDENTS' AWARENESS ABOUT THE HARMS OF MICROPLASTICS ON THE HUMAN BODY
THE IMPACT OF COMPLAINTS ON QUALITY OF LIFE, PSYCHOLOGICAL WELL-BEING AND HEALTH OF MEDICAL WORKERS
DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE FOR PATIENTS "STUDYING THE OPINION OF PATIENTS' SATISFACTION WITH NURSE INDEPENDENT APPOINTMENT AT THE LEVEL OF PRIMARY HEALTH CARE"